Symptom burden &amp; quality of life among patients receiving second-line treatment of metastatic colorectal cancer

Walker, Mark S.; Pharm, Elaine Yu; Kerr, Jiandong; Yim, Yeun Mi; Stepanski, Edward J.; Schwartzberg, Lee S.

doi:10.1186/1756-0500-5-314

Cited by 15 publications

(29 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20–22, 24 The sample sizes ranged from 104 21 to 5442 22 patients and three of the five studies had less than 250 patients. 21, 23, 24 Across the 5 studies, the weighted grand mean age was 59.5 years and gender distribution was approximately equal. In three of the five studies, 21, 23, 24 100% of the patients had CRC and in one study, 20 49.6% of the patients had colon cancer and 50.4% had rectal cancer.…”

Section: Resultsmentioning

confidence: 98%

“…20–22, 24 The fifth study used a descriptive, longitudinal, repeated-measures design. 23 Across these five studies, retrospective data were used in four. 20–22, 24 The sample sizes ranged from 104 21 to 5442 22 patients and three of the five studies had less than 250 patients.…”

Section: Resultsmentioning

confidence: 99%

“…Two tables were generated to summarize the three studies of multiple co-occurring symptoms in patients with CRC who received CTX alone 20, 22, 24 (Table 1) and the two studies of patients with CRC who received CTX with targeted therapies 21, 23 (Table 2). Both tables are organized using the following evaluation criteria: author, year, purpose, study design (i.e., cross-sectional, longitudinal), sample characteristics (i.e., sample size, age, gender, diagnosis, setting, time since diagnosis, previous treatments, current treatments, use of targeted therapy), symptom assessments (i.e., instruments, number of symptoms assessed, dimensions of symptoms assessed), major findings, strengths, and limitations.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

A Review of the Literature on Multiple Co-occurring Symptoms in Patients With Colorectal Cancer Who Received Chemotherapy Alone or Chemotherapy With Targeted Therapies

et al. 2016

View full text Add to dashboard Cite

Background Patients with colorectal cancer (CRC) rarely experience a single symptom associated with their disease and its treatment. Objective Purpose of this literature review was to summarize the current state of knowledge of multiple co-occurring symptoms in CRC patients who received chemotherapy alone or chemotherapy with targeted therapies. Methods Comprehensive literature search was conducted from 1990 to 2014. These studies were evaluated in terms of the occurrence of multiple, co-occurring symptoms in CRC patients who received CTX alone or CTX with targeted therapies; the most common symptom assessment and quality of life (QOL) instruments used; and the associations identified between select demographic and treatment characteristics, QOL, and multiple co-occurring symptoms. Results Only five studies met this review’s inclusion criteria. Two studies compared symptoms in patients who received CTX alone or CTX with targeted therapies and only one study reported on symptom occurrence. Of the five studies identified, only two used the same instrument to assess symptoms and only two studies evaluated for associations between demographic and treatment characteristics and symptom burden, as well as QOL outcomes. Conclusions Given the larger number of patients with CRC, as well as the increased number of CRC patients who will receive targeted therapies with or without CTX, future studies need to describe the occurrence, severity, and distress of multiple co-occurring symptoms and their impact on CRC patients’ QOL. Implications for Practice To deliver effective symptom management interventions, the most common, severe, and distressing symptoms that CRC patients experience need to be identified.

show abstract

Section: Resultsmentioning

confidence: 98%

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

A Review of the Literature on Multiple Co-occurring Symptoms in Patients With Colorectal Cancer Who Received Chemotherapy Alone or Chemotherapy With Targeted Therapies

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The evaluation of symptoms within the context of these RCTs is limited because most studies used the National Cancer Institute's (NCI's) Common Terminology Criteria for Adverse Events (CTCAE) (22)(23)(24)(25)(26). Only four studies used valid and reliable symptom assessment instruments to evaluate various dimensions of the symptom experience (i.e., occurrence, severity, distress) in patients with GI cancers receiving CTX (27)(28)(29)(30).…”

Section: Introductionmentioning

confidence: 99%

“…Only one retrospective, cohort study evaluated the symptom experience of patients with GI cancers on targeted therapies (30). In this study, differences in the symptom burden of patients with CRC who received second-line treatments that contained bevacizumab or cetuximab with or without CTX were evaluated.…”

Section: Introductionmentioning

confidence: 99%

Differences in symptom occurrence, severity, and distress ratings between patients with gastrointestinal cancers who received chemotherapy alone or chemotherapy with targeted therapy

Tantoy

Dhruva

Cataldo

et al. 2017

J. Gastrointest. Oncol.

View full text Add to dashboard Cite

Background: Approximately 28% of patients with gastrointestinal (GI) cancers will receive targeted therapy (TT) because of the associated increases in survival. Only four studies have examined the symptom experience of these patients. To date, no studies have evaluated for differences in symptom occurrence, severity, and distress between patients who received chemotherapy (CTX) alone (n=304) or CTX with TT (n=93).Methods: Patients completed self-report questionnaires, approximately one week after they received CTX.A modified version of the Memorial Symptom Assessment Scale (MSAS) was used to obtain data on symptom occurrence, severity, and distress. Binary logistic regression analyses were used to test for differences in symptom occurrence rates between the two treatment groups. Ordinal logistic regression analyses were used to test for differences in severity and distress ratings between the two treatment groups.Results: Patients who received CTX with TT were significantly younger (P=0.009); were diagnosed with cancer longer (P=0.004); had a higher number of prior treatments (P=0.024); had metastatic disease, specifically to the liver (P<0.001); had a diagnosis of anal, colon, rectum, or colorectal cancer (CRC) (P<0.001); and were positive for detection of B-Raf proto-oncogene, serine/threonine kinase (BRAF) and Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations (both P<0.001). In addition, CTX treatment regimens were significantly different between the two groups (P<0.001). After controlling for significant covariates, patients who received TT reported lower occurrence rates for lack of energy, cough, feeling drowsy, and difficulty sleeping (all, P<0.05). Patients who received TT reported lower severity scores for dry mouth (P=0.034) and change in the way food tastes (P=0.035). However, they reported higher severity scores for "I don't look like myself" (P=0.026).No differences in symptom distress scores were found between the two treatment groups.Conclusions: This study is the first to evaluate for differences in the symptom experience of GI cancer patients who received CTX alone or CTX with TT using a multidimensional symptom assessment scale.While between group differences in patients' symptom experiences were identified, both treatment groups warrant ongoing assessments to optimally manage their symptoms.

show abstract

Symptoms during chemotherapy in colorectal cancer patients

Röhrl

Guren

Småstuen

et al. 2019

Support Care Cancer

View full text Add to dashboard Cite

Symptom burden & quality of life among patients receiving second-line treatment of metastatic colorectal cancer

Cited by 15 publications

References 26 publications

A Review of the Literature on Multiple Co-occurring Symptoms in Patients With Colorectal Cancer Who Received Chemotherapy Alone or Chemotherapy With Targeted Therapies

A Review of the Literature on Multiple Co-occurring Symptoms in Patients With Colorectal Cancer Who Received Chemotherapy Alone or Chemotherapy With Targeted Therapies

Differences in symptom occurrence, severity, and distress ratings between patients with gastrointestinal cancers who received chemotherapy alone or chemotherapy with targeted therapy

Symptoms during chemotherapy in colorectal cancer patients

Contact Info

Product

Resources

About